Fig. 4From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in SpainPlane of incremental costs (£) vs. incremental QALYs and Cost-effectiveness acceptability curve: Certolizumab pegol + MTX vs Etanercept + MTX; Certolizumab pegol + MTX vs Infliximab (3 mg/kg) + MTX and Certolizumab pegol + MTX vs Infliximab (5 mg/kg) + MTXBack to article page